N. Stojanovic, Z. Hassan, M. Wirth, P. Wenzel, M. Beyer, C. Schäfer, P. Brand, A. Kroemer, R.H. Stauber, R.M. Schmid, A. Arlt, A. Sellmer, S. Mahboobi, R. Rad, M. Reichert, D. Saur, O.H. Krämer and G. Schneider. (10-10-2016).

Oncogene advance online publication, 2016, doi:10.1038/onc.2016.344

Department: 

Research Area C

Abstract: 

Mutation of p53 is a frequent genetic lesion in pancreatic cancer being an unmet clinical challenge. Mutants of p53 have lost the tumour-suppressive functions of wild type p53. In addition, p53 mutants exert tumour-promoting functions, qualifying them as important therapeutic targets. Here, we show that the class I histone deacetylases HDAC1 and HDAC2 contribute to maintain the expression of p53 mutants in human and genetically defined murine pancreatic cancer cells. Our data reveal that the inhibition of these HDACs with small molecule HDAC inhibitors (HDACi), as well as the specific genetic elimination of HDAC1 and HDAC2, reduce the expression of mutant p53 mRNA and protein levels. We further show that HDAC1, HDAC2 and MYC directly bind to the TP53 gene and that MYC recruitment drops upon HDAC inhibitor treatment. Therefore, our results illustrate a previously unrecognized class I HDAC-dependent control of the TP53 gene and provide evidence for a contribution of MYC. A combined approach targeting HDAC1/HDAC2 and MYC may present a novel and molecularly defined strategy to target mutant p53 in pancreatic cancer.